Article
A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors
This research paper discusses the growing prevalence of immune-related diabetes mellitus (irDM) caused by immune checkpoint inhibitors (ICPis). It proposes a two-pronged approach to advance knowledge and understanding of irDM, focusing on both the scientific and patient-centered aspects. The paper suggests a multidisciplinary effort to improve characterization, standardization, and treatment of irDM.
Multi-omics approaches for precision obesity management
The purpose of this review is to provide an overview of the different types of omics data: genomics, epigenomics, transcriptomics, proteomics, metabolomics and illustrate how a multi-omics approach can be fundamental for the implementation of precision obesity management.
Multi-omics approaches for precision obesity management Read More »
Multi-omics approaches for precision obesity management
The research paper discusses the multifactorial nature of obesity and the limitations of traditional lifestyle interventions. It aims to illustrate how a multi-omics approach, encompassing various types of omics data, can facilitate precision obesity management by identifying specific biomarkers and guiding individualized treatment plans. This integration is proposed to shift the focus from a one-size-fits-all strategy to tailored prevention and treatment of obesity and its related diseases.
Multi-omics approaches for precision obesity management Read More »
Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program
In Asia, diabetes-associated death due to cardiorenal diseases were 2–3 times higher in women than men which might be due to gender disparity in quality of care and health habits.
Obesity in South and Southeast Asia—A new consensus on care and management
Our group of obesity specialists from Bangladesh, Brunei Darussalam, India, Indonesia, Malaysia, Philippines, Singapore, Sri Lanka, Thailand, and Viet Nam undertook to develop consensus recommendations for management and care of adults and children with obesity in South and Southeast Asia.
Obesity in South and Southeast Asia—A new consensus on care and management Read More »
Changes in hyperglycaemia-related testing for prediabetes and type 2 diabetes mellitus management: a prospective, cross-sectional survey of 16 years of general practice data from Australia
This study examined 16 years of hyperglycaemia-related testing in Australia and found that the proportion of encounters for prediabetes and type 2 diabetes management has increased over time. GPs were influenced by changes in national insurance and clinical guidelines, but there was also evidence of “unendorsed” testing. This has significant resource implications and calls for an economic analysis to lower the risk threshold for prediabetes screening. Ongoing data is needed to inform clinical practice and policy in Australia.
Type 2 diabetes
Type 2 diabetes, which constitutes nearly 90% of the 537 million diabetes cases globally, is rapidly increasing, particularly among children and young adults. The research emphasizes the importance of early detection and management to prevent complications, highlights the potential of precision medicine and novel therapies, and discusses the barriers to effectively addressing the diabetes epidemic.
Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation
The ongoing obesity epidemic represents a global public health crisis that contributes to poor health outcomes, reduced quality of life, and >2.8 million deaths each year.
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Subcutaneous semaglutide is effective for weight loss in individuals with obesity without diabetes, achieving an average reduction of 11.85% from baseline compared to placebo. However, the treatment is associated with a higher risk of gastrointestinal adverse events, treatment discontinuation, and serious adverse event